MEDICA the world’s largest medical device show, will once again be meeting in person. Running parallel to the exhibit will be the Medical Tech conference which is managed by the leading industry associations SPECTARIS and ZVEI. Here you will learn about the German and international market environment, as well as the implementation of modern procedures and methods in clinical practice.[...]
Perivision (https://perivision.io/), a Swiss Start-Up focused on the Ophthalmic side of medicine, recently asked BioPortUSA for help with the reimbursement side of things in the USA.[...]
Mark Lesselroth joins host Bill Kenney from MEET to uncover the myths and learn the realities for Life Science companies entering the US Market.[...]
From September 26 to October 1st, the exceptional Swiss National Startup Teams of the Venture Leaders Life Sciences 2020 and Medtech 2021 had their residence at Swissnex Boston for a joint roadshow: 17 top-class startups presented their innovations to international investors, fine-tuned their pitches, and participated in a series of business development workshops to deepen their knowledge of the American market and regulations. Let's immerse ourselves in this highly inspiring atmosphere.[...]
The team at BioPortUSA has been asked to present to a group of 17 Swiss Medical Device start-ups on what it takes to be successful in the USA including how to navigate the regulatory pathway. [...]
I was talking with a friend of mine in Germany who was raving about the benefits associated with the Hydrus Microstent (Ivantis) for glaucoma patients. This is a device that when combined with cataract surgery can help lower the eye pressure of a patient suffering from glaucoma. She focused on the features and benefits for both the patient and the physician. In the United States, a widely used alternative to the Hydrus Stent is the iStent from Glaucos. On July 2 the stock was trading at $82.45, on July 14th it was down to $57.82 and by July 26th it had dropped to $47.99. What happened? CMS (Center of Medicare and Medicaid Services) was rumored to slash the reimbursement from $500/procedure to $20. Since both the iStent and the Hydrus Mircostent use the same CPT code (billing code), there is a high likelihood that if this change by CMS goes through, that very few Ophthalmologist in the USA will use this product as part of their procedure because they will be making next to nothing. In Germany, no one is looking at the stock price or the reimbursement code! They are focused on what a great technology it is, and how it will help the patient.[...]
The ASKO Foundation along with the Saarbrücken Chamber of Commerce, the European Institute at the University of the Saarland, Germany, along with the German American Institute of the Saarland have invited Mark Lesselroth, CEO of BioPortUSA to participate in a discussion regarding the current trade relations between European Union, USA and China.[...]
Social Media
